Reuters logo
BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
November 28, 2017 / 12:16 PM / in 13 days

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

Nov 28 (Reuters) - Aptevo Therapeutics Inc:

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

* APTEVO THERAPEUTICS INC- ‍EXPECTS TO FILE 2 IND APPLICATIONS IN 2018 FOR 2 BISPECIFIC ANTIBODY CANDIDATES, APVO436 AND APVO210​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below